Indian pathology labs that hope to generate business from the United Kingdom may have to invest in a front-end operation there because of issues related to legal liability in the event of faulty analysis of samples.
A team of 13 chief executives of different hospitals under the UK's National Health System (NHS) visited India recently to study the healthcare delivery service. Some Indian pathology labs have worked towards using India's relative cost advantage to attract basic pathology lab business from the UK and the United States.
Indian pathology lab chains such as SRL Ranbaxy and Metropolis have had their main lab accredited to the College of American Pathologists to project the credibility needed for outsourcing opportunities.
The NHS has already outsourced pathology samples to India's SRL Ranbaxy and Metropolis Health Services as part of a pilot project. The NHS team, however, felt that any meaningful outsourcing of analysis of pathology samples to India was not going to be easy in the present situation.
Continue reading: http://www.rediff.com/money/2005/nov/17bpo.htm
0 comments:
Post a Comment